| Serial Number | 97427897 |
| Word Mark | INOVIQ |
| Filing Date | Wednesday, May 25, 2022 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, November 26, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, October 15, 2024 |
| Description of Mark | The mark consists of the wording "INOVIQ" to the right of a design of three concentric rings of dots. |
| Goods and Services | Pharmaceutical, biotechnology and medical preparations and substances for the prevention, diagnosis or treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases; pharmaceutical, biotechnology and medical preparations and substances for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical purposes, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; immunological antibodies for medical use; biological preparations for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for medical purposes; biological preparations for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for pharmaceutical purposes; biological substances for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing monoclonal antibodies for use in medicine; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer, viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, pharmaceutical and biochemical anti-cancer substances, products for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases, and testing materials, namely, diagnostic test strips, immunoassays, PCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic biomarker reagents for medical purposes; reagents for use in diagnostic tests for medical purposes; protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic reagents for in-vitro use for medical purposes, reagents for in-vitro laboratory use for medical purposes, reagents for use in diagnostic tests for medical purposes, diagnostic reagents for medical use for sale in kit form; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical purposes; pharmaceutical, biotechnology and medical preparations and substances for medical use, namely, immunotherapeutic agents for the treatment of cancer; nucleic acid substances for use in genetic probe assay kits for medical use; preparations for the treatment, reconstruction and repair of antibodies, namely, biological preparations for pharmaceutical purposes |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Biological reagents for scientific and research use for molecular targets for drug and vaccine development; reagents for medical research applications; reagents for medical research applications, namely, molecular targets for drug and vaccine development; biological reagents for use in molecular biology for research purposes; reagents for medical diagnosis research applications |
| Goods and Services | Advisory services relating to medical diagnostic products; advisory services relating to medical diagnostic products, namely, medical diagnostic products for extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; Medical diagnostic testing services; medical diagnostic screening services in the field of diagnostic preparations |
| Goods and Services | Biotechnology medical apparatus for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases; medical diagnostic apparatus and instruments for testing biofluids, plasma, serum, saliva, urine and cell cultures for sale in kit form; biotechnology medical apparatus, namely, medical apparatus for the capture of extracellular vesicles |
| Goods and Services | Scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; vaccine screening, in the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; providing diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposes, namely, research services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; diagnostic and research services and screening in the nature of research services in the field of diagnostic preparations; preparation of reports relating to medical, scientific and technical research; provision of information relating to medical, scientific and technical research; research and development of products; research and development of products, namely, new therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell line, namely, culturing of cells for others for scientific research purposes |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, December 30, 0001 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, December 30, 0001 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, June 1, 2022 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, June 1, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, January 1, 0001 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | INOVIQ Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Notting Hill, VIC 3168 AU |
| Party Name | INOVIQ Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Notting Hill, VIC 3168 AU |
| Event Date | Event Description |
| Saturday, May 28, 2022 | NEW APPLICATION ENTERED |
| Wednesday, June 1, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, June 2, 2022 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Friday, March 10, 2023 | ASSIGNED TO EXAMINER |
| Tuesday, March 21, 2023 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 21, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, March 21, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, June 20, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Tuesday, June 20, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Thursday, September 21, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, September 21, 2023 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Monday, February 12, 2024 | ASSIGNED TO LIE |
| Monday, February 12, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, February 12, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, February 12, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, March 12, 2024 | FINAL REFUSAL WRITTEN |
| Tuesday, March 12, 2024 | FINAL REFUSAL E-MAILED |
| Tuesday, March 12, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Tuesday, June 11, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Tuesday, June 11, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, September 9, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, September 9, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, September 9, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Thursday, September 12, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, September 12, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, September 12, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, September 12, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, September 12, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, September 25, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 15, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 15, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 26, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |